Stephen Pereira

Jul 17, 2017

Stephen Pereira has been appointed to Immunovia's scientific advisory board. Pereira is a professor of hepatology and gastroenterology at University College London and is an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and the Royal Free Hospital. 

More Like This

Oct 13, 2017

Fred Hirsch

Biocept said that Fred Hirsch has joined its clinical advisory board. Hirsch is a professor of medicine and pathology at the University of Colorado Cancer Center.

Oct 11, 2017

Tom Civik

Tom Civik has been appointed as chief commercial officer of Foundation Medicine and will start his new position in mid November. Most recently, he was a vice president and franchise leader at Genentech, where he was responsible for several oncology products. Earlier, he held various commercial positions at Sanofi-Synthelabo. Civik holds a BA from St. Norbert College and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

Oct 10, 2017

John Kenny

John Kenny has been appointed CEO of Meridian Bioscience, effective Oct. 9. He replaces John Kraeutler who is stepping down to become executive chairman. Kraeutler announced in May his plans to resign from the company as CEO. Kenny also was appointed to Meridian's board, effective Oct. 9. Kenny was most recently senior vice president, general manager, North America at Siemens Healthcare. He has also held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics.

Oct 03, 2017

Alan Copperman

Alan Copperman has joined health information firm Sema4 as its chief medical officer. Copperman is director of the division of reproductive endocrinology and infertility, and vice chairman of the department of obstetrics, gynecology, and reproductive science at the Icahn School of Medicine at Mount Sinai. He also is managing partner at Reproductive Medicine Associates of New York. 

Oct 03, 2017

Jeffrey Rona

Jeffrey Rona has resigned from his position as CFO of Great Basin Scientific, effective October 6, 2017.

Oct 03, 2017

Paul Eros

Novacyt has appointed Paul Eros as commercial director, effective Nov. 1. Eros joins Novacyt from DiaSorin, where he was VP of molecular marketing for more than five years. He has also worked for Becton Dickinson and Roche Diagnostics

Oct 03, 2017

Jeffery Luber

Atlas Genetics announced today that Jeffrey Luber has been appointed CEO and John Clarkson, current founding CEO, will become Executive Chairman. Mr. Luber joins the board with experience in the life sciences industry, including roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae. Prior to this, Luber was CEO of Exact Sciences, where he executed its turnaround and strategic transaction with Genzyme. 

Oct 02, 2017

Doug Fisher, Jeffrey Cossman

Precipio has elected Doug Fisher and Jeffrey Cossman to its board in order to fill existing vacancies. Fisher will serve on Precipio's audit committee and compensation committee. Cossman will serve on the company's compensation committee and will chair the nominating and corporate governance committee. 

Fisher is currently executive-in-resident at venture capital firm InterWest Partners, where he has worked since March 2009. He is also chief business officer at Sera Prognostics. Cossman is founder of the United States Diagnostic Standards, where he also served as CEO and chairman. Prior to that, he was CSO and a member of the board of The Critical Path Institute and as medical director of Gene Logic. 

Sep 29, 2017

Michael Epplen

Michael Epplen has been promoted to president of Sunquest Information Systems. Epplen had been serving as chief operating officer of Sunquest as well as president of Atlas Medical, which Sunquest parent company Roper Technologies acquired two years ago. He previously spent five years as CEO of Data Innovations, another company that Roper bought in 2015.

Sep 29, 2017

Timothy Ring and David Melcher

Becton Dickenson announced today that Timothy Ring and David Melcher have joined its board of directors. Ring has served as chairman and CEO of Bard since August 2003. He previously joined Bard in 1992 and has served as VP of human resources, group VP of Bard International, and in additional roles. Ring is also a director of Quest Diagnostics, a trustee for the New Jersey Health Foundation, and a board member for the Advanced Medical Technology Association. Melcher has been president and CEO of the Aerospace Industries Association since 2015. Prior to AIA, Melcher was president and CEO of Exelis, a spinoff of ITT Corporation. In addition to being a director for Bard, Melcher is also a member of the Federal Aviation Administration's NextGen Advisory Committe, providing advice on policy-level issues for US aviation modernization.  

Sep 27, 2017

Greg Richard

Interpace Diagnostics has promoted Greg Richard to the position of chief commercial officer. He previously served as senior vice president of commercial operations. Richard has worked in the healthcare business in various positions for more than 25 years, starting in sales at Aetna, and then moving to Genentech as the director of managed care. He also served as vice president of managed care for Quest Diagnostics, vice president of sales for the Northeast division of LabCorp, and worked for several privately held companies focused in various areas including specialty CROs, molecular diagnostics, and anatomic pathology services. 

Sep 27, 2017

Eric Brouwer

SQI Diagnostics announced Eric Brouwer has joined the firm as chief scientific officer. He will be responsible for executing SQI's R&D program. Brouwer was most recently CSO of Trinity Biotech and CEO of Trinity's Swedish subsidiary Fiomi Diagnostics. Before that he spent 15 years at Abbott Laboratories. 

Sep 20, 2017

Micah Litow

Micah Litow has joined cancer screening test firm Preora Diagnostics as its chief marketing and business development officer. He previously was at IA Collaborative where he led the healthcare practice. Before that, he was director of innovation at Leica Biosystems.

Sep 20, 2017

Patrick Young

True Health named Patrick Young to its board of directors. Young is president of Population Health for Hackensack Meridian Health. True Health provides biomarker testing cardiovascular diseases, diabetes, autoimmune disorders, metabolic conditions, and other ailments. It began offering its hereditary cancer test called genTrue earlier this year. 

Sep 19, 2017

Michael Korn

Michael Korn has been appointed the chief medical officer of Caris Life Sciences, where he will guide the firm's research efforts and clinical strategies for the Adapt Biotargeting System and Caris Molecular Intelligence tumor profiling. Korn is a professor of medicine in the division of hematology/concology at the University of California, San Francisco, and he replaces John Marshal, who was CMO for Caris on a part-time basis. Marshall will continue as chairman of the Precision Oncology Alliance, which is powered by Caris.